Atara Q3 2022 Earnings Report
Key Takeaways
Atara Biotherapeutics announced a positive CHMP opinion for Ebvallo and continues to advance its pipeline, including ATA188 for progressive MS. The company's cash, cash equivalents, and short-term investments totaled $265.4 million as of September 30, 2022. Net loss for the quarter was $84.1 million, or $0.82 per share.
Received positive CHMP opinion for Ebvallo, positioning it as a potential first-ever approved allogeneic off-the-shelf T-cell therapy.
Presented new biomarker imaging data for ATA188 showing less brain atrophy and potential remyelination in patients with progressive MS.
Phase 1 study of ATA2271 enrollment resumed.
Atara believes that its cash and investments as of September 30, 2022 will be sufficient to fund the Company’s planned operations into Q1 2024
Atara
Atara
Forward Guidance
Atara believes that its cash and investments as of September 30, 2022, together with potential cash inflows from Pierre Fabre and the expected reductions in operating cash burn, will be sufficient to fund the Company’s planned operations into Q1 2024.